Submitted by Biogen
As a purpose-driven company, Biogen seeks ways to reinforce our commitment to climate, health and equity. Our newly released 2021 Year in Review reports on our progress on these and other priorities to create a healthier, more equitable and sustainable world. Highlights include:
With its Year In Review, Biogen also kicked off the 20th anniversary of the Biogen Foundation and the Biogen Community Lab, which have served more than 3 million people in 50+ countries, inspiring students’ life-long journeys in science, reducing health disparities and helping neighbors in need.
This kind of progress is possible, in part, due to Biogen’s commitment to governance of corporate responsibility issues. The company has formalized Board oversight of ESG, and once again tied a portion of employees’ and executive officers’ compensation to ESG metrics.
Biogen’s 2021 Year In Review is aligned with GRI, SASB, the World Economic Forum Stakeholder Capitalism Metrics, the UN SDGs and the Task Force on Climate-Related Financial Disclosures (TCFD). Not only is Biogen a signatory of the United Nations Global Compact, this year the company has become an early adopter of the UN’s new reporting standards.
Read more by visiting Biogen’s Year in Review website.
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
More from Biogen